Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Ogeda SA
→
Astellas Pharma

Acquisition · Cash + milestone payments · announced Apr 3, 2017

View in network
  1. Announced

    Apr 3, 2017

  2. Closed

    May 17, 2017

Economics

Cash + milestone payments()

Pre-deal · pre-deal mark: 2017, year precision · rounding grid ±$100M · Astellas press release — Ogeda SA acquisition, 2017

EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates

Target

Ogeda SA

Menopause · Clinical / therapeutic

HQ Gosselies, Belgium · Founded 1999

Drug discovery company developing fezolinetant for menopausal vasomotor symptoms; formerly Euroscreen SA

  • Astellas Pharma press release (May 17, 2017)
  • PR Newswire - Astellas completes acquisition (May 2017)
  • Astellas newsroom - newsroom.astellas.com

Acquirer

Astellas Pharma

Healthcare

HQ Tokyo, Japan

Japanese pharmaceutical company focused on urology, oncology, and women's health

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Added fezolinetant (NK3 receptor antagonist) for menopausal vasomotor symptoms — later FDA-approved as VEOZAH in 2023

Evidence ladder

Press only — no primary filingValue disclosed
  1. Secondary (press / IR)

    Astellas Pharma press release (May 17, 2017)

  2. Secondary (press / IR)

    PR Newswire

Limitations

  • Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
  • EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates
  • Pre-deal valuation sourced from: Astellas press release — Ogeda SA acquisition, 2017. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Menopause

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
KaNDy TherapeuticsBayerAug 11, 2020same evidence class

Other verified deals by Astellas Pharma

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Astellas Pharma are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Ogeda SA (Menopause). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.